PEDIATRIC INFLAMMATORY BOWEL DISEASE

Similar documents
Treatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

IBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition

Efficacy and Safety of Treatment for Pediatric IBD

INFLAMMATORY BOWEL DISEASE. Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic

Medical Therapy for Pediatric IBD: Efficacy and Safety

NEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL

My Child Has Inflammatory Bowel Disease : Why? What now? What s next?

Efficacy and Safety of Treatment for Pediatric IBD

Definitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)

ULCERATIVE COLITIS. Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants

Inflammatory Bowel Disease When is diarrhea not just diarrhea?

SURGICAL MANAGEMENT OF ULCERATIVE COLITIS

The Spectrum of IBD. Inflammatory Bowel Disease. Symptoms. Epidemiology. Tests for IBD. CD or UC? Inflamatory Bowel Disease. Fernando Vega, M.D.

Speaker Introduction

CCFA. Crohns Disease vs UC: What is the best treatment for me? November

The National Association of Crohn s and Colitis of Trinidad and Tobago CROHN S DISEASE AND ULCERATIVE COLITIS GENERAL PATIENT INFORMATION

Patho Basic Chronic Inflammatory Bowel Diseases. Jürg Vosbeck Pathology

Crohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine

Dietary Options for Inflammatory Bowel Disease

Laurie S. Conklin, M.D. Inflammatory Bowel Disease Program Children s National Medical Center

September 12, 2015 Millie D. Long MD, MPH, FACG

Beyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center

Slide 1 Medications in inflammatory bowel disease a primer for health care providers. Slide 2. Slide 3 Theory of pathogenesis. IBD - epidemiology

Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease

Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals

New and Emerging Therapies in IBD. Sarah Streett MD, AGAF Clinical Associate Professor of Medicine Stanford University

Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014

Ali Keshavarzian MD Rush University Medical Center

IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital

Moderately to severely active ulcerative colitis

Treatment Options. Suresh Pola, MD Kaiser San Diego

Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease

Biologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida

How to manage your IBD patient: Tips for diagnosis and care

Beyond the Bowel: Extraintestinal Manifestations of Inflammatory Bowel Disease

Title: Author: Journal:

Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων

Top 10 Things you need to know about IBD. Suresh Pola, MD Kaiser San Diego

Improving outcome of Inflammatory Bowel Disease in children

The ABCs of Inflammatory Bowel Disease. Jennifer Choi, M.D. Associate Director March 31, 2012

Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists

Azathioprine for Induction and Maintenance of Remission in Crohn s Disease

Understanding Inflammatory Bowel Diseases (IBD):

Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy

Indications for use of Infliximab

I B D. etter than this. isease UNDERSTANDING INFLAMMATORY BOWEL DISEASES

P a g e 1. Inflammatory Bowel Disease Guidelines

New treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital

Garrick Brown, MD. Digestive Health Specialists Tacoma Gig Harbor

IBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD

What is IBD and Why Me?

Ulcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13

My child was diagnosed IBD, Now What?

INFLAMMATORY BOWEL DISEASE

INFLAMMATORY BOWEL DISEASE (IBD): CROHN S DISEASE

Hot Topics In Nutrition & IBD January 6, Kate Vance, RD Wael N. Sayej, MD

How do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD

Current management options and recent advances in IBD

Dr David Epstein Vincent Pallotti Hospital and University of Cape Town

Michael D. Kreines, M.D.

Doncaster & Bassetlaw Medicines Formulary

Crohn s Disease. Resident Lecture 1/17/19

Medical Management of Inflammatory Bowel Disease

Pediatric Inflammatory Bowel Diseases

Dr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest)

What is ulcerative colitis?

Pediatric Inflammatory Bowel Disease in Less Than 30 Minutes

Management of the Hospitalized IBD Patient. Drew DuPont MD

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010

Crohn s Disease: The First Visit

IBD in teenagers Biological and Transition

What Will This Talk Cover? 101: The Basics of Inflammatory Bowel Disease. Terms & Abbreviations. What Is Normal GI Anatomy?

Mucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium

What is Inflammatory Bowel Disease (IBD)?

Policy #: 472 Latest Review Date: May 2017

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012

Update in Pediatric IBD: 2018

Managing. Inflammatory Bowel Disease. Slide 1. Slide 2. Slide 3. Disclosures. Vijay Yajnik, MD., PhD 01/25/14. None relevant to this talk

INFLAMMATORY BOWEL DISEASE

Judith Collins, MD Assoc Professor of Gastroenterology & Hepatology Inflammatory Bowel Disease Program, OHSU

WHAT IS ULCERATIVE COLITIS?

Disease Management Strategies for Moderate to Severe IBD in Adults

Implementation of disease and safety predictors during disease management in UC

OUNCE OF PREVENTION WORTH A POUND OF CURE

Positioning Biologics in Ulcerative Colitis

Medical therapies and IBD

New Perspectives on the Diagnosis and Management of IBD. Disclosures

Treatment of Pediatric IBD: What is Different?

Treatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10

What is Crohn's disease?

Inflammatory Bowel Disease

Clinical Study Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis

ACG Clinical Guideline: Management of Crohn s Disease in Adults

Inflammatory Bowel Disease

What do we need for diagnosis of IBD

Understanding Your Benefits and Risks

Transcription:

PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease of the gastrointestinal tract ~ Can affect any area of GI tract 2 Major Types: ~ Crohn s Disease ~ Ulcerative Colitis Other Types: ~ Indeterminate colitis ~ Very Early Onset (VEO-IBD) Has relapsing and remitting course ~ Goal is to induce and stay in remission Exact pathogenesis poorly understood 1

2

Environmental Factors Smoking is a risk factor for CD (OR = 1.76; 95% CI: 1.40-2.22) - Protective against UC Appendectomy is a risk factor for CD - Protective against UC (OR = 0.31; 95% CI: 0.25-0.38) Vitamin D deficiency risk factor for aggressive CD and UC Western diet risk factor for both UC and CD - High sugar - High animal protein - Decreased complex carbohydrates/plant fibers 3

Alliment Pharm May 2015; 42(2) 4

How common is IBD? Incidence increasing among children Approx 1.6 million Americans with IBD Pediatric Incidence: ~ CD: 10.7/100,000 ~ UC: 12.2/100,000 Pediatric Prevalence: ~ 45,000 100,000 children with IBD ~ 100,000 cases diagnosed annually Age of Onset 5

4/6/18 Children Vs. Adults Similarities with adults: ~ Disease pathophysiology similar ~ Many of the same treatments Differences from adults: ~ Lack of data ~ Not as many treatment options ~ Growth and development issues Presentation Extraintestinal Symptoms Arthropathies Optho: ~ Episcleritis ~ Uveitis Derm: ~ Erythema Nodosum ~ Pyoderma Gangrenosum Liver: ~ Primary Sclerosing Cholangitis 6

Initial workup CBC with differential ~ Anemia ~ Thrombocytosis CMP ~ Hypoalbuminemia Inflammatory markers ~ CRP, ESR ~ Stool calprotectin Infectious studies ~ Stool culture, O&P, C.diff Differential Diagnosis Bacteria: Non Infectious: ~ C.diff ~ HSP ~ Yersinia ~ Behcet s ~ TB ~ Celiac Virus: ~ Immunodeficiency ~ HIV ~ Eating disorder ~ CMV ~ Appendicitis ~ EBV ~ Functional Parasites: ~ Amoebiasis ~ Giardiasis Refer to GI 7

Crohn s Endoscopy 8

UC Endoscopy 9

Histology Small Bowel Imaging Upper GI with small bowel follow through MR Enterography Small Bowel Imaging Capsule Endoscopy 10

Goals of IBD Treatment Improve growth and nutrition Improve quality of life Maximize therapeutic response Minimize toxicity Prevent disease complications Maximize adherence Promote psychological health INDUCE REMISSION = CLINICAL RESPONSE 11

Goals of IBD Treatment Improve growth and nutrition Improve quality of life Maximize therapeutic response Minimize toxicity Prevent disease complications Maximize adherence Promote psychological health INDUCE REMISSION = CLINICAL RESPONSE MUCOSAL HEALING 12

Step Up Approach Future Directions Step Down?? Corticosteroids Used to induce remission only ~ Try to wean off as soon as possible Oral, rectal and IV forms available Suppresses active inflammation Can be used for Crohn s and UC ~ Usually started for disease flares ~ Can serve as bridge to maintenance medication Problem with side effects ~ Less with budesonide (Entocort) 13

Aminosalicylates Aminosalicylates (5-ASA) Often first line treatment for mild UC ~ unclear efficacy in Crohn s Oral and rectal preparations available ~ combination most effective for distal disease Locally reduce inflammation in the bowel wall ~ no systemic effects Can be used for induction and maintenance Generally well tolerated ~ side effects (headaches, GI symptoms) more with sulfasalazine Adherence can be an issue due to large number of pills Immunomodulators Thiopurines (6-MP, Azathioprine), Methotrexate Suppress immune response that triggers intestinal damage Used for moderate-severe Crohn s and UC ~ Usually for maintenance therapy ~ Takes weeks to reach maximum efficacy levels Side effects: ~ Bone marrow suppression ~ Hepatitis ~ Teratogenic ~ LYMPHOMA 14

Biologics Anti TNF-α monoclonal antibodies ~ Pro-inflammatory cytokine involved in IBD ~ Neutralizes TNF-α and down-regulates other proinflammatory cytokines Anti- integrin antibodies ~ Prevents attachment of T cells to vessel walls in gut Anti-IL 12 and 23 cytokines ~ Disrupts cytokine signaling in inflammatory response Used for severe Crohn s and UC Side effects include infections, infusion reactions, lymphoma 15

4/6/18 Surgery Usually last resort for medically refractory disease Can involve limited resection, partial colectomy, total colectomy with pouch creation Total colectomy curative for UC 16

Exclusive Enteral Nutrition First line for induction therapy for Crohn s in Europe 100% of nutrition by formula ~ No differences in type of formula As effective as steroids in inducing mucosal healing Exact mechanism unknown ~ Possible effect through changing microbiota Cons: ~ Difficult to sustain ~ Cost ~ Resource demands 17

THANK YOU 18